Related Experiment Video

Updated: Jul 10, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Cardiotoxicity of Targeted Therapies in Hematologic Malignancies: From Molecular Mechanisms to Clinical Management

Mengmeng Lin1, Shanshan Shi2, Chong Zhang3

  • 1Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, School of Medicine, Affiliated Hangzhou First People's Hospital, Westlake University, 261 Huansha Road, Hangzhou, Zhejiang, 310006, China.

Current Treatment Options in Oncology
|July 9, 2026
PubMed
Abstract

Insights

Targeted therapies for blood cancers improve survival but can cause heart problems. Personalized monitoring and cardio-oncology teams are essential for managing these cardiovascular toxicities while continuing cancer treatment.

Area of Science:

  • Cardio-oncology
  • Hematologic Malignancies
  • Cardiovascular Toxicology

Background:

  • The treatment of hematologic malignancies has shifted towards targeted therapies, improving survival rates.
  • These novel agents, including proteasome inhibitors, tyrosine kinase inhibitors, and epigenetic regulators, are associated with significant cardiovascular toxicities.
  • Current management strategies for these toxicities are hindered by inconsistent adverse event reporting and complex risk stratification tools.

Purpose of the Study:

  • To advocate for a streamlined, personalized surveillance strategy for cardiovascular toxicities in patients receiving targeted cancer therapies.
  • To emphasize the importance of comprehensive baseline cardiovascular assessment and tailored monitoring based on treatment specifics and patient risk.
  • To highlight the critical role of multidisciplinary cardio-oncology teams in managing emergent cardiotoxicity and preventing treatment interruptions.

Main Methods:

  • Review of current literature and clinical practices in cardio-oncology.
  • Analysis of challenges in managing cardiovascular adverse events associated with targeted cancer therapies.
  • Proposal of a personalized surveillance and management framework.

Main Results:

  • The shift to targeted therapies necessitates a proactive approach to managing cardiovascular complications.
  • Personalized monitoring, informed by drug mechanisms and patient risk, is crucial for early detection of cardiotoxicity.
  • Multidisciplinary cardio-oncology teams are vital for effective management of cardiac issues, ensuring continuity of cancer care.

Conclusions:

  • A personalized, risk-stratified surveillance approach is essential for patients undergoing targeted therapy for hematologic malignancies.
  • Early detection and proactive management of cardiovascular toxicities by cardio-oncology teams can optimize oncologic outcomes and patient quality of life.
  • Balancing the benefits of potent antitumor therapies with the protection of cardiovascular function is paramount.
Keywords:
Cardio-oncologyCardiotoxicityHematologic cancerTargeted therapy

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...